Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabis in movement disorders.

K R Müller-Vahl1, H Kolbe, U Schneider

  • 1Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Germany. Mueller-Vahl.Kirsten@MH-Hannover.de

Forschende Komplementarmedizin
|January 8, 2000
PubMed
Summary

Cannabinoids may treat movement disorders by acting on the central cannabinoid system within the basal ganglia. Research suggests therapeutic potential for tics, Parkinson's disease dyskinesia, tremor, and dystonia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is the Continued Use of a Small Quantity of Salicylic Acid Detrimental to Health?

Buffalo medical and surgical journal·2023
Same author

Randomized double-blind sham-controlled trial of thalamic versus GPi stimulation in patients with severe medically refractory Gilles de la Tourette syndrome.

Brain stimulation·2021
Same author

Author Correction: Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder.

Scientific reports·2020
Same author

Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder.

Scientific reports·2019
Same author

Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette Syndrome.

European journal of neurology·2013
Same author

[Dronabinol in neuropsychiatric diseases].

Schmerz (Berlin, Germany)·2013

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Central cannabinoid receptors are abundant in basal ganglia output nuclei, crucial for motor control.
  • Endogenous cannabinoid transmission modulates neurotransmitters (GABA, glutamate, dopamine) within the basal ganglia.
  • Basal ganglia-thalamo-cortical loop dysfunction underlies hyperkinetic and hypokinetic movement disorders.

Purpose of the Study:

  • To explore the role of the central cannabinoid system in movement disorder pathophysiology.
  • To review the therapeutic potential of cannabinoids in treating various movement disorders.

Main Methods:

  • Review of existing clinical trials and evidence regarding cannabinoid use in movement disorders.
  • Analysis of the neurobiological mechanisms involving cannabinoid receptors in the basal ganglia.

Main Results:

  • Limited clinical trials suggest cannabinoids are beneficial for Tourette syndrome tics, Parkinson's disease levodopa-induced dyskinesia, tremor, and dystonia.
  • Cannabinoid antagonists may be useful for chorea in Huntington's disease and hypokinetic parkinsonian syndromes.

Conclusions:

  • The central cannabinoid system is implicated in the pathophysiology of movement disorders.
  • Cannabinoids show therapeutic promise for several movement disorders, warranting further controlled studies.

Related Experiment Videos